ProShares Ultra NASDAQ Biotechnology
BIB
BIB
17 hedge funds and large institutions have $22.6M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Holders
17
Holding in Top 10
–
Calls
$8.68M
Puts
$17.9M
Top Buyers
| 1 | +$1.28M | |
| 2 | +$847K | |
| 3 | +$641K | |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$325K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$195K |
Top Sellers
| 1 | -$2.06M | |
| 2 | -$1.77M | |
| 3 | -$1.39M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$682K |
| 5 |
Citigroup
New York
|
-$396K |